Priscilla Brastianos
Massachusetts General Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Priscilla Brastianos as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 07:20 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03994796 · Genetic Testing in Guiding Treatment for Patients With Brain MetastasesAlliance for Clinical Trials in Oncology · active not recruiting · CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm · study chair
- Ph2NCT03279692 · Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade MeningiomaMassachusetts General Hospital · active not recruiting · High Grade Meningioma · principal investigator
- Ph2NCT02939300 · Ipilimumab and Nivolumab in Leptomeningeal MetastasesMassachusetts General Hospital · completed · Leptomeningeal Carcinomatosis · principal investigator
- Ph2NCT02523014 · Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive MeningiomasAlliance for Clinical Trials in Oncology · recruiting · Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 07:20 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Elucidating resistance mechanisms and enhancing response to immune checkpoint blockade in central nervous system metastases from breast cancerR01CA294793 · NCI · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2024 to 2026 · $2,082,604 awarded in 2026Same name and institution; not confirmed by an ID
- Using MRI and circulating tumor DNA to improve the interpretation of response to immunotherapy and targeted therapy in CNS metastasesR01CA244975 · NCI · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2020 to 2024 · $646,356 awarded in 2024Same name and institution; not confirmed by an ID
- Identification of genomic drivers of brain metastases in lung adenocarcinomaR01CA227156 · NCI · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2018 to 2022 · $695,450 awarded in 2022Same name and institution; not confirmed by an ID
- Identification of genomic drivers of brain metastases in renal cell carcinomaR21CA220253 · NCI · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2018 to 2019 · $181,867 awarded in 2019Same name and institution; not confirmed by an ID
- Impact of genetic alterations in meningioma on natural history and therapeutic responseR21NS099844 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2016 to 2017 · $215,484 awarded in 2017Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Alliance for Clinical Trials in Oncology Member Site CoreU10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis · fiscal years 2014 to 2026Named on NCT03994796
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 07:20 UTC. The ranking covers the 200 most relevant of 10 PubMed records, and a shared surname and initials can bring in a namesake. All 10 on PubMed
- BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas.N Engl J Med · 2023135 citationsRCR 14.5
- Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis.Nat Med · 2020128 citationsRCR 5.0
- Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations.J Clin Oncol · 2023102 citationsRCR 9.7
- Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas.Nat Commun · 202289 citationsRCR 6.6
- 81 citationsRCR 4.1
- Genomic and transcriptomic correlates of immunotherapy response within the tumor microenvironment of leptomeningeal metastases.Nat Commun · 202166 citationsRCR 3.0
- 65 citationsRCR 4.8
- Phase I Study and Cell-Free DNA Analysis of T-DM1 and Metronomic Temozolomide for Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases.Clin Cancer Res · 202323 citationsRCR 2.2
- Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance.Neuro Oncol · 20247 citationsRCR 0.7